ArticleACS omega2024
Elastin-like Recombinamers as a Biotechnological Platform for the Development of Cytokine-Functionalized Materials.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncostatin M (OSM) and leukemia inhibitory factor (LIF) are pleiotropic cytokines from the interkeukine-6 family, associated with several disorders, and present significant potential in biomedicine. However, their therapeutic use is highly constrained by factors such as short circulating half-life and narrow therapeutic window. The conjugation of cytokines with elastin-like recombinamers (ELR) holds the potential to circumvent these limitations due to the ability of self-assembling upon a thermal stimulus, remarkable biocompatibility, and ease of processing. In this work, we report on the development of genetically engineered hybrid ELR conjugates by fusing the DNA sequences coding for murine/human OSM and LIF into the C-terminus of an ELR. The resulting hybrid fusion proteins demonstrated to retain the thermal properties of the ELR, which enabled the nonchromatographic purification by employing simple hot/cold cycles. Nanoparticles and free-standing films were obtained by self-assembly and solvent casting, respectively, using environmentally friendly processes (mild conditions and water-based methods). Both materials were characterized for their properties, revealing the absence of hemotoxicity upon contact with red blood cells and promising features for potential therapeutic applications. Overall, this work represents a step forward in the development of advanced functionalized biomaterials suitable for localized cytokine therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.